Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.37 |
| ▸ | CHRNG | P07510 | 1/20 | 0.37 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | CHRND | Q07001 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 5/20 | 0.36 |
| ▸ | CA1 | P00915 | 5/20 | 0.36 |
| ▸ | CA2 | P00918 | 5/20 | 0.36 |
| ▸ | CA9 | Q16790 | 5/20 | 0.36 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.36 |
| ▸ | CD44 | P16070 | 1/20 | 0.34 |
| ▸ | CA3 | P07451 | 2/20 | 0.33 |
| ▸ | CA4 | P22748 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8549332 | 0.88 | CA12 (0.35) | CA12CA1CA2CA9CA3 | |
| SCHEMBL5453679 | 0.83 | ALDH1A1 (0.39) | LMNAMEN1KMT2A | |
| SCHEMBL8393015 | 0.78 | HPGD (0.45) | MEN1PKMKMT2A | |
| SCHEMBL3141276 | 0.76 | ALDH1A1 (0.55) | LMNACA1CA2 | |
| SCHEMBL29712852 | 0.76 | ALDH1A1 (0.55) | LMNACA1CA2 | |
| SCHEMBL1922201 | 0.76 | SMN1; SMN2 (0.55) | MEN1KMT2AL3MBTL1 | |
| SCHEMBL92141 | 0.75 | CA12 (0.50) | LMNACA12CA1CA2CA9 | |
| SCHEMBL10630611 | 0.75 | CD44 (0.39) | LMNACA12CA1CA2CA9 | |
| SCHEMBL8617912 | 0.75 | GPR27 (0.42) | LMNAGPR27CD44GRIN2DGRIN3B | |
| SCHEMBL8545974 | 0.75 | ALDH1A1 (0.44) | LMNAPKMKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420679-B2 | Aminothiazole derivatives and their use as CRF receptor ligands | SANOFI (FR) | 2013-04-16 | — | — | US | disclosed |
| US-20070281919-A1 | Aminothiazole Derivatives And Their Use As CRF Receptor Ligands | SANOFI-AVENTIS (FR) | 2007-12-06 | — | — | US | disclosed |
| EP-1200419-B1 | AMINOTHIAZOLE DERIVATIVES AND THEIR USE AS CRF RECEPTOR LIGANDS | SANOFI SYNTHELABO (FR) | 2004-04-14 | — | — | EP | disclosed |
| US-6586456-B1 | Corticotropin releasing factor (CRF) antagonists such as (4-(2-chloro-4-methoxy-5-methylphenyl)-5-methylthiazol-2-yl)(( (1-(3-fluoro-4-methylphenyl)-2-methoxyethyl))prop-2-ynylamine, prepared by alkylation with propagyl bromide | SANOFI-SYNTHELABO (FR) | 2003-07-01 | — | — | US | disclosed |
| EP-1200419-A1 | AMINOTHIAZOLE DERIVATIVES AND THEIR USE AS CRF RECEPTOR LIGANDS | SANOFI-SYNTHELABO (FR) | 2002-05-02 | — | — | EP | disclosed |
| WO-2001005776-A1 | AMINOTHIAZOLE DERIVATIVES AND THEIR USE AS CRF RECEPTOR LIGANDS | SANOFI-SYNTHELABO (FR) | 2001-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281919-A1 | Aminothiazole Derivatives And Their Use As CRF Receptor Ligands | CRH, CRHR1, CRHR2 | LMNA 4796/4885CHRNA1 491/4885CHRNG 775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.